News
MSD's Sac-TMT delivers in first phase 3 readout
MSD's TROP2-targeting antibody-drug conjugate sac-TMT, licensed from China's Kelun, has improved survival in a late-stage endometrial cancer trial.
News
Novartis reveals more data behind Pluvicto expansion bid
Novartis has reported new data to support its drive to expand the label of its radioligand therapy Pluvicto in prostate cancer.
News
Another LAG-3 setback as Regeneron drug fails phase 3 trial
Regeneron's LAG-3 inhibitor fianlimab has missed the mark in a highly anticipated melanoma trial, hitting its share price.
R&D
Sponsored
Company Profile – Inventus
Inventus devices and technology solutions have been deployed in 1,000+ clinical trials and are certified in 70+ countries.
News
Trial miss doesn't dent Biogen's faith in Alzheimer's drug
Biogen will advance its tau-targeting Alzheimer's disease drug diranersen into phase 3, even though it missed the main endpoint in a midstage trial.
Debates & Insights
News
Press Releases
Editor's Picks
Editor's Picks
